CD8A and neoplasm: Combining current first-line therapies (radiotherapy and temozolomide) with mIDH1 inhibitors and PD-L1-targeted immune checkpoint inhibitors (ICI) has enhanced tumor shrinkage in mIDH1 glioma-bearing mice, alleviated T cell exhaustion, and supported the formation of memory CD8+T cells.